Ocular Therapeutix
CompanyUnited StatesFounded 2006
Ocular Therapeutix develops one asset, approved (dexamethasone in burns). Mostly small molecule acting on NF-κB signalling, apoptosis and NR3C1; based in the United States, founded in 2006.
- 1
- Asset
- Furthest
- Approved
- 8
- Trials
- 0
- Signals
Pipeline
1Glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive effects
Approved, Small molecule, NF-κB signalling, Apoptosis, burns, Conjunctivitis, Allergic
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials22
- Signals1
- Similar companies6
Updated 12 Oct 2026 · 81 sources